Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | DRD3 | P35462 | 6/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198379 | 1.00 | DRD2 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4195809 | 0.92 | PGR (0.50) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4194699 | 0.88 | PGR (0.52) | DRD2DRD3SIGMAR1PGRHTR1A | |
| SCHEMBL4194704 | 0.88 | PGR (0.52) | DRD2DRD3SIGMAR1PGRHTR1A | |
| SCHEMBL1546821 | 0.87 | ALDH1A1 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL1546929 | 0.87 | ALDH1A1 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL1546766 | 0.86 | ALDH1A1 (0.46) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL1546768 | 0.86 | ALDH1A1 (0.46) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL1546115 | 0.85 | DRD2 (0.55) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4190597 | 0.85 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | DRD2 116/4885DRD3 228/4885DRD1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.